<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/258349-combination-of-hmg-coa-reductase-inhibitor-with-phosphodiesterase-4-inhibitors-for-the-treatmentof-inflammatory-pulmonary-diseases by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 05:52:55 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 258349:COMBINATION OF HMG-COA REDUCTASE INHIBITOR WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENTOF INFLAMMATORY PULMONARY DISEASES</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">COMBINATION OF HMG-COA REDUCTASE INHIBITOR WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENTOF INFLAMMATORY PULMONARY DISEASES</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>FORM 2<br>
THE PATENTS ACT, 1970 (39 of 1970)<br>
&amp; THE PATENTS RULES, 2003<br>
COMPLETE SPECIFICATION<br>
[See section 10, Rule 13]<br><br><br>
COMBINATION	OF	HMG-COA<br>
REDUCTASE	INHIBITOR	WITH<br>
PHOSPHODIESTERASE 4 INHIBITORS<br>
FOR THE TREATMENT OF<br>
INFLAMMATORY	PULMONARY<br>
DISEASES;<br>
NYCOMED GMBH, A CORPORATION<br>
ORGANIZED AND EXISTING UNDER THE<br>
LAWS OF GERMANY, WHOSE ADDRESS<br>
IS	BYK-GULDEN-STR.      2,      78467<br>
KONSTANZ, GERMANY.<br><br>
THE FOLLOWING SPECIFICATION PARTICULARLY DESCRIBES THE INVENTION AND THE MANNER IN WHICH IT IS TO BE PERFORMED.<br><br><br>
Technical Field<br>
The present invention relates to the combination of certain known therapeutic compounds for thera¬peutic purposes. The substances used in the combinations according to the invention are known ac¬tive agents from the phosphodiesterase 4 (PDE4) inhibitor class and active agents from the HMG-CoA-reductase inhibitor class.<br>
Background Art<br>
Statins are widely used as cholesterol lowering therapeutic agents. They reduce cholesterol levels through competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the key enzyme that regulates cholesterol synthesis. The cholesterol-lowering effect of statins is also due to an increase in the uptake of cholesterol by cells as a result of intracellular cholesterol depletion and enhanced expression of low-density lipoprotein (LDL) receptors.<br>
However, statins exhibit properties that are beyond their lipid-lowering effects. These non-lipid-lowe-ring properties involve the inhibition of the isoprenoid pathway including the cholesterol precursor me-valonate which is required as a precursor for the prenylation of a number of proteins leading to a change in function [Drugs of Today; 2004;40: 975-990]. For example simvastatin modulates chemo-kine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages [Veillard NR et al; Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages; Atherosclerosis; 2005 Nov 28; Epub ahead of print]. Statins also have a potential role as antioxidants leading to downregulation of inflammation [Drugs of Today; 2004; 40: 975-990J. Recent research data demonstrated that statins inhibit the induction of the major histocompatibility (MHC) class II expression by interferon-gamma (IFN-gamma), leading to repression of MHC ll-mediated T-cell activation. Fur¬thermore, statins inhibit the expression of specific cell surface receptors on monocytes, adhesion molecules and also integrin-dependent leucocyte adhesion [Timely Top Med Cardiovasc Dis; 2005; 9: E3]. Statins exhibit additional effects on inflammation by decreasing IL-6, IL-8, and MCP-1 synthesis in human vascular smooth muscle cells (VSMC) in vitro [Cardiovas Res; 2003; 59: 755-66]. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts [Am J Respir Cell Mol Biol. 2005; 32: 290-300]. Furthermore, statins increase bioavailability of nitric oxide. Cerivas-tatin increased eNOS expression a NO release in human endothelial cells [J Physiol Pharmacol. 2002; 53:585-95], In vivo statins exert anti-inflammatory effects in many models of inflammatory airway dis-<br><br>
eases like asthma and COPD. Simvastatin was shown to inhibit pulmonary inflammatory cell accumu¬lation and il_-4 and IL-5 release into the alveolar lumen after allergeH challenge in mice [J Immunol. 2004; 172: 2903-8]. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hyper¬tension in rat lungs [Am J Respir Crit Care Med. 2005; 172: 987-93]. Overall statins exhibit inhibitory properties on inflammation and modulation on the immune system.<br>
In the international patent application WOOO/48626 (University of Washington) aerosol compositions of HMG-CoA reductase inhibitors for inhibiting inflammation associated witn a pulmonary disease, such as asthma, interstitial pneumonitis, emphysema, chronic bronchitis, £dult respiratory distress syndro¬me (ARDS) and cystic fibrosis, are described. In EP1275388 (Takeda) several statins are described as useful for the treatment of TNFa associated diseases such as inflammatory diseases including asthma and COPD. In US20050119330 the use of HMG-CoA reductase inhibitors is descibed for the treatment of lung proliferative vascular disorders, such as for example pulmonary hypertension and pulmonary fibrosis.<br>
There is pressing, need to improve the treatment of inflammatory puli710nary diseases like asthma and COPD. These inflammatory diseases are characterized by multifact<?rial pathologies. Several inflam¬matory mediators are involved as well as various cell types. Therefore, in medical practice for the treatment of e.g. asthma and COPD the targeting of a single mediate or cell type has not lead to sat¬isfactory results. For both asthma and COPD at present combination" therapies are used but in many instances with limited success especially in COPD.<br/>
Cyclic nucleotide phosphodiesterase (PDE) inhibitors, particularly innibitors of type 4 (PDE4), are use¬ful in the treatment of a variety of allergic and inflammatory diseases-for example in respiratory dis¬eases, such as asthma and chronic obstructive pulmonary disease.<br>
HMG-CoA reductase inhibitors, by a route different from PDE4 inhibitors. are also useful in the treat¬ment of inflammatory diseases.<br>
It would be desirable to provide combinations and methods of treatment that can take advantage of the different therapeutic pathways of a PDE4 inhibitor and a HMG-0&gt;A reductase inhibitor to more effectively treat inflammatory disorders, in particular asthma and CO^D-<br>
Description of the invention<br>
It has now been found that the combined use of a PDE4 inhibitor an^ a HMG-CoA reductase inhibitor potentiates the anti-inflammatory effect of either component alone.<br>
Therefore, according to a first aspect of the present invention there \0 provided a pharmaceutical com-<br><br>
position comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor or a phar¬maceutically acceptable salt thereof, an amount of a HMG-CoA reductase inhibitor or a pharmaceuti¬cally acceptable salt thereof, wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease, and at least one pharmaceutically acceptable auxiliary.<br>
The above-mentioned pharmaceutical composition provides for the administration of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof with a HMG-CoA reductase inhibitor or a pharmaceuti¬cally acceptable salt thereof and is thus presented as a single formulation.<br>
Alternatively, the PDE4 inhibitor or a pharmaceutically acceptable salt thereof and the HMG-CoA re¬ductase inhibitor or a pharmaceutically acceptable salt thereof may be presented as separate formula¬tions, wherein at least one of those formulations comprises a PDE4 inhibitor or a pharmaceutically acceptable salt thereof and at least one comprises a HMG-CoA reductase inhibitor or a pharmaceuti¬cally acceptable salt thereof.<br>
Thus, there is further provided:<br>
A combination product comprising the components: (A) an amount of a PDE4 inhibitor or a pharma¬ceutically acceptable salt thereof; (B) an amount of a HMG-CoA reductase inhibitor or a pharmaceuti¬cally acceptable salt thereof; wherein the first and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease and wherein each of the components (A) and (B) is formulated in admixture with at least one pharmaceutically ac¬ceptable auxiliary.<br>
A kit comprising the components: (A) a pharmaceutical formulation including an amount of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof, in admixture with at least one pharmaceutically acceptable auxiliary; (B) a pharmaceutical formulation including an amount of a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, in admixture with at least one pharmaceutically acceptable auxiliary; wherein the first and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease.<br>
The combinations according to the invention can be used for the preventive or curative treatment of inflammatory pulmonary diseases, such as, for example, asthma, COPD, sclerosis, alveolitis, sarcoi¬dosis, idiopathic pulmonary fibrosis and pulmonary hypertension.<br>
Therefore, further aspects of the invention are:<br><br>
Combinabon of a PDE4 inhibitor or a pharmaceuticaliy acceptable salt thereof and a HMG-CoA reduc¬tase inhibitor or a pharmaceuticaliy acceptable salt thereof for use as a medicament.<br>
Combination of a PDE4 inhibitor or a pharmaceuticaliy acceptable salt thereof and a HMG-CoA reduc¬tase inhibitor or a pharmaceuticaliy acceptable salt thereof for the preventive or curative treatment of an inflammatory pulmonary disease.<br>
Pharmaceutical composition, combination product or kit, as described in the preceding paragraphs, for use as a medicament.<br>
Pharmaceutical composition, combination product or kit, as described in the preceding paragraphs, for the preventive or curative treatment of an inflammatory pulmonary disease.<br>
The use of a PDE4 inhibitor or a pharmaceuticaliy acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceuticaliy acceptable salt thereof for the manufacture of a medicament, in particu¬lar the pharmaceutical composition according to the invention, for the preventive or curative treatment of an inflammatory pulmonary disease.<br>
Another aspect of the present invention is the use of a PDE4 inhibitor or a pharmaceuticaliy accept¬able salt thereof and a HMG-CoA reductase inhibitor or a pharmaceuticaliy acceptable salt thereof for the manufacture of a sequential or separate co-administrable medicament, in particular the combina¬tion product or kit according to the invention, for the preventive or curative treatment of an inflamma¬tory pulmonary disease.<br>
Still another aspect of the present invention is a method for the preventive or curative treatment of an inflammatory pulmonary disease comprising administering to a patient in need thereof a pharmaceuti¬cal composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor or a pharmaceuticaliy acceptable salt thereof, an amount of a HMG-CoA reductase inhibitor or a pharma¬ceuticaliy acceptable salt thereof, wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease, and at least one pharmaceuticaliy acceptable auxiliary.<br>
A further aspect of the present invention is a method for the preventive or curative treatment of an inflammatory pulmonary disease comprising administering to a patient in need thereof a combination product comprising the components:<br>
(A)	an amount of a PDE4 inhibitor or a pharmaceuticaliy acceptable sail thereof;<br>
(B)	an amount of a HMG-CoA reductase inhibitor or a pharmaceuticaliy acceptable salt thereof; wherein the first and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease;<br><br>
wherein each of the components (A) and (B) is formulated in admixture with at least one pharmaceuti¬cally acceptable auxiliary; and wherein the components (A) and (B) are administered simultaneously, sequentially or separately.<br>
The pharmaceutical compositions according to the invention may be prepared by mixing the first ac¬tive agent with the second active agent.<br>
In the above-mentioned mixing process the first active agent and the second active agent can<br>
a)	in a first step be mixed as such, afterwards be processed with at least one pharmaceutically ac¬<br>
ceptable auxiliary and finally, for example, be pressed to tablets or caplets<br>
or<br>
b)	in a first step separately be processed with at least one pharmaceutically acceptable auxiliary to<br>
give granules or pellets containing each only one of the two active agents; the pellets or granules for<br>
their part then can be mixed in an appropriate ratio and either pressed - optionally with further phar¬<br>
maceutically acceptable auxiliaries - to give, for example tablets or caplets, or can be filled in loose<br>
form in capsules.<br>
Therefore, in a still further aspect of the present invention there is provided a process for the prepara¬tion of a pharmaceutical composition which comprises mixing a first active agent, which is a PDE4 inhibitor or a pharmaceutically acceptable salt thereof with a second active agent, which is a HMG CoA-reductase inhibitor or a pharmaceutically acceptable salt thereof.<br>
Simultaneous administration of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof can be preferably accomplished, by administering to the patient in need of inflammatory pulmonary disease therapy the pharmaceutical composition according to the invention in one dosage form, such as for example in a single capsule, tablet or injection.<br>
Components (A) and (B) of the combination product as well as of the kit may be administered sequen¬tially or separately over the course of the preventive or curative treatment of an inflammatory pulmo¬nary disease.<br>
Sequential or separate administration of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof can be preferably accomplished, by administering to the patient in need of inflammatory pulmonary disease therapy components (A) and (B) of the combination product or the kit according to the invention in (multiple) separate dosage forms, such as for example, in separate capsules, tablets or injections. The compo¬nents (A) and (B) of the combination product or the kit according to the invention can also be adminis¬tered simultaneously, for example by swallowing the two tablets containing the both active agents at<br><br>
the same time, or by using an inhaler system, which contains both active agents in separate contain¬ers, but deliver them together.<br>
In an alternative, one of the components (A) and (B) may be formulated as tablet or capsule and the other component may be formulated for administration, for example, by injection or inhalation.<br>
Sequential administration encompasses a short time period between the administration of components (A) and (B) of the combination product or the kit according to the invention (for example, the time that is needed to swallow one tablet after the other).<br>
Separate administration encompasses both relatively short and relatively long time periods between the administration of components (A) and (B) of the combination product or the kit according to the invention. However, for the purposes of the present invention at least one of the components is admin¬istered while the other component is still having an effect on the patient being treated. In a preferred embodiment of the invention the effect on the patient being treated is a synergistic effect.<br>
The combined administration of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, either in form of the pharmaceutical composition, combination product or kit according to the invention, lead to an effective preventive or curative treatment of the inflammatory pulmonary disease, and in a preferred embodi¬ment is superior to the use of either active compound alone. Moreover, in a particularly preferred em¬bodiment, the combined administration of a PDE4 inhibitor or a pharmaceutically acceptable thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof shows a synergistic efficacy for treating an inflammatory pulmonary disease.<br>
As used herein, the term "synergistic" refers to the combination of a PDE4 inhibitor or a Pharmaceuti¬cally acceptable salt thereof with a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof either in form of the pharmaceutical composition, combination product or kit according to the invention having an efficacy for the preventive or curative treatment of an inflammatory pulmonary disease that is greater than would be expected from the sum of their individuals effects. The synergis¬tic effects of the embodiments of the present invention encompass additional unexpected advantages for the preventive or curative treatment of inflammatory pulmonary diseases. Such additional advan¬tages may include, but are not limited to, lowering the required dose of one or more of the active com¬pounds of the combination, reducing the side effects of one or more of the active compounds of the combination or rendering one or more of the active compounds more tolerable to the patient in need of an inflammatory pulmonary disease therapy. The combined administration of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof may also be useful for decreasing the required number of separate dosages,<br><br>
thus, potentially improving compliance of the patient in need of inflammatory pulmonary disease ther¬apy.<br>
The therapeutic effect of the combinations according to the invention may be also observed with re¬gard to the fast decline in lung function that is a hallmark of COPD, and effects may be observed re¬garding the systemic inflammation that is also a characteristic of COPD. The long-term effect of the combinations according to the invention will be the conservation of lung function and putatively less co-morbidity (based on effects on the systemic inflammation).<br>
The term "active compound" as used herein refers to a compound useful in the preventive or curative treatment of a disease.<br>
The term "effective amount" as used herein refers to a therapeutically effective amount for treating an inflammatory pulmonary disease. In case of a combination therapy the term "effective amount" refers to the sum of the amounts of the combination partners, which is therapeutically effective for the pre¬ventive or curative treatment of an inflammatory pulmonary disease.<br>
The term "patient" includes both humans and other mammals. In a preferred embodiment of the inven¬tion the term "patient" stands for humans.<br>
The term "PDE4 inhibitor" as used herein refers to an active compound that is capable of reducing the physiological effect of the PDE4 isoenzyme of phosphodiesterase preferentially over other isoenzyme of phosphodiesterase.<br>
Non-limiting examples of PDE4 inhibitors, which may be usefully employed in the pharmaceutical compositions, combination products and kits according to the invention are listed in Table 1.<br>
In one embodiment of the present invention the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST (CAS-No. 162401-32-3), ROFLUMILAST-N-Oxide (CAS-No. 292135-78-5), CILOMI-LAST (CAS-No. 153259-65-5), AWD-12-281 (CAS-No. 257892-33-4), TOFIMILAST (CAS-No. 185954-27-2), TETOMILAST (CAS-No. 145739-56-6), LIRIMILAST (CAS-No. 329306-27-6), L-869298 (CAS-No. 362718-73-8), OGLEMILAST (CAS-No. 778576-62-8), 2-{4-[(4aS, 8aR)-4-(3,4-dimethoxy-phenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-pipehdin-1-yl}-acetamide (hereinafter referred to as COMPOUND A; CAS-No. 449760-58-1) and the pharmaceutically acceptable salts of these compounds.<br>
In another embodiment of the present invention the PDE4 inhibitor is selected from the group consist¬ing of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide.<br><br>
In another embodiment of the present invention the PDE4 inhibitor is ROFLUMILAST.<br>
In another embodiment of the present invention the PDE4 inhibitor is ROFLUMILAST-N-oxide.<br>
In another embodiment of the present invention the PDE4 inhibitor is CILOMILAST or a pharmaceuti¬cally acceptable salt thereof.<br>
In another embodiment of the present invention preferred pharmaceutically acceptable salts of CILO¬MILAST are the lithium, sodium, ethylene diamine and tromethamine salt of CILOMILAST. A particu¬larly preferred pharmaceutically acceptable salt of CILOMILAST is the sodium salt of CILOMILAST. Another particularly preferred pharmaceutically acceptable salt of CILOMILAST is the lithium salt of CILOMILAST. As an example for a hydrate of CILOMILAST may be mentioned the monohydrate of the lithium salt of CILOMILAST.<br>
In another embodiment of the present invention the PDE4 inhibitor is AWD-12-281 or a pharmaceuti¬cally acceptable salt thereof.<br>
In another embodiment of the present invention a preferred pharmaceutically acceptable salt of AWD-12-281 is the sodium salt of AWD-12-281.<br>
in another embodiment of the present invention the PDE4 inhibitor is TOFIMiLAST or a pharmaceuti¬cally acceptable salt thereof.<br>
In another embodiment of the present invention the PDE4 inhibitor is TETOMILAST or a pharmaceuti¬cally acceptable salt thereof.<br>
In another embodiment of the present invention the PDE4 inhibitor is LIRIMILAST or a pharmaceuti¬cally acceptable salt thereof.<br>
In another embodiment of the present invention the PDE4 inhibitor is L-869298 or a pharmaceutically acceptable salt thereof.<br>
In another embodiment of the present invention the PDE4 inhibitor is OGLEMILAST or a pharmaceuti¬cally acceptable salt thereof.<br>
In another embodiment of the present invention preferred pharmaceutically acceptable salts of OGLE¬MILAST are the mono-sodium and the di-sodium salt of OGLEMILAST.<br><br>
WO 2008/0037(11<br><br>
PCT/EP2007/056683<br><br>
In another embodiment of the present invention the PDE4 inhibitor is COMPOUND A or a pharmaceu-tically acceptable salt thereof.<br>
Table 1<br><br><br><br><br><br>
Additional information with regard to the preparation, suitable dosage forms and dose ranges of the PDE4 inhibitors ROFLUMILAST, ROFLUMILAST-N-oxide and the pharmaceutically acceptable salts thereof can be found in the following patents/patent applications: WO9501338, WO03070279 and WO2006032676.<br>
Additional information with regard to the preparation, suitable dosage forms and dose ranges of the PDE4 inhibitors CILOMILAST, AWD-12-281, TOFIMILAST, TETOMILAST, LIRIMILAST, L-869298, OGLEMILAST, COMPOUND A and the pharmaceutically acceptable salts thereof can be found in the following patents/patent applications: W09319749, WO9809946, W09955696, WO9639408, WO9209586, EP0731099, WO0170738, WO04089940 and WO02064584.<br>
The term "HMG-CoA reductase inhibitor" as used herein refers to competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyzes an early, rate-limiting step in cholesterol biosynthesis, thereby lowering levels of cholesterol and triglyceride in hyperiipidemic pa¬tients.<br>
Non-limiting examples of HMG-CoA reductase inhibitors, which may be usefully employed in the pharmaceutical compositions, combination products and kits according to the invention are listed in Table 2.<br><br>
In one embodiment of the present invention the HMG-CoA reductase inhibitor is selected from the group consisting of LOVASTATIN (CAS-No. 75330-75-5), PRAVASTATIN (CAS-No. 081093-37-0), SIMVASTATIN (CAS-No. 079902-63-9), ATORVASTATIN (CAS-No. 134523-00-5), FLUVASTATIN (093957-54-1), ROSUVASTATIN (CAS-No. 287714-41-4), PRAVASTATIN (CAS-No. 147511-69-1), BERVASTATIN (CAS-No. 132017-01-7), DALVASTATIN (CAS-No. 132100-55-1), GLENVASTATIN (CAS-No. 122254-45-9) and the pharmaceutical^ acceptable salts of these compounds.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is LOVASTATIN or a pharmaceutical ly acceptable salt thereof.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is PRAVASTATIN or a pharmaceutical^ acceptable salt thereof.<br>
In another embodiment of the present invention preferred pharmaceutical^ acceptable salts of PRA¬VASTATIN are the potassium, lithium, sodium and hemi-calcium salt of PRAVASTATIN. A particularly preferred pharmaceutical^ acceptable salt of PRAVASTATIN is the sodium salt of PRAVASTATIN.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is SIMVASTATIN or a pharmaceutical^ acceptable salt thereof.<br>
In another embodiment of the present invention the pharmaceutical^ acceptable salt of SIMVASTA¬TIN is the sodium salt of SIMVASTATIN.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is ATORVASTATIN or a pharmaceutical^ acceptable salt thereof.<br>
In another embodiment of the present invention preferred pharmaceutical^ acceptable salts of ATORVASTATIN are the potassium, sodium and the hemi-calcium saltof ATORVASTATIN. A particu¬larly preferred pharmaceutical^ acceptable salt of ATORVASTATIN is the hemi-calcium salt of ATORVASTATIN. As an example for a hydrate of ATORVASTATIN may be mentioned the trihydrate and the sesqui-hydrate of the hemi-calcium salt of ATORVASTATIN.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is FLUVASTATIN or a pharmaceutical^ acceptable salt thereof.<br>
In another embodiment of the present invention the pharmaceutical^ acceptable salt of FLUVASTA¬TIN is the sodium salt of FLUVASTATIN.<br><br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutical^ acceptable salt thereof.<br>
In another embodiment of the present invention preferred pharmaceutical^ acceptable salts of ROSU-V AST WIN are the potassium, lithium, sodium, hemi-ma^esium and the hemi-caldum salt at ROSU¬VASTATIN. A particularly preferred pharmaceutical^ acceptable salt of ROSUVASTATIN is the hemi-calcium salt of ROSUVASTATIN. Another particularly preferred pharmaceutical^ acceptable salt of ROSUVASTATIN is the sodium salt of ROSUVASTATIN.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is PRAVASTATIN or a pharmaceutical^ acceptable salt thereof.<br>
In another embodiment of the present invention preferred pharmaceutical^ acceptable salts of PRA¬VASTATIN are the potassium, sodium and the hemi-calcium salt of PRAVASTATIN. A particularly preferred pharmaceutical^ acceptable salt of PRAVASTATIN is the hemi-calcium salt of PRAVAS¬TATIN.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is BERVASTATIN or a pharmaceutical^ acceptable salt thereof.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is DALVASTATIN or a pharmaceutical^ acceptable salt thereof.<br>
In another embodiment of the present invention the HMG-CoA reductase inhibitor is GLENVASTATIN or a pharmaceutical^ acceptable salt thereof.<br><br>
Table 2:<br><br><br><br><br><br>
The HMG-CoA reductase inhibitors LOVASTATIN, PRAVASTATIN, SIMVASTATIN, ATORVASTATIN, FLUVASTATIN, ROSUVASTATIN and PITAVASTATIN listed in Table 2 are commercially available. The person skilled in the art is familiar with suitable formulations and dose ranges of these com¬pounds. Additional information with regard to the preparation, suitable dosage forms and dose ranges of these HMG-CoA reductase inhibitors and the pharmaceutically acceptable salts thereof can be found in the following patents/patent applications: EP022478, DE3122499, EP033538, EP0247633, EP0114027, EP0521471 and EP0304063.<br><br>
Additional information with regard to the preparation, suitable dosage forms and dose ranges of the HMG-CoA reductase inhibitors BERVASTATIN, DALVASTATIN, GLENVASTATIN and the pharma¬ceutical^ acceptable salts thereof can be found in the following patents/patent applications: EP0380392, WO8905639 and EP0307342.<br>
Salts encompassed within the term "pharmaceutical^ acceptable salts" are not restricted to the spe¬cific examples given above. The term refers to non-toxic salts of the PDE4 inhibitors or the HMG-CoA reductase inhibitors, which are generally prepared by reacting a free base with a suitable organic or inorganic acid (acid addition salt) or by reacting the free acid with a suitable organic or inorganic base. Acid addition salts include, but are not limited to, hydrochlorides, hydrobromides, phosphates, nitrates, sulfates, acetates, citrates, D-gluconates, benzoates, 2-(4-hydroxybenzoyl)benzoates,.butyrates, sul-fosalicylates, maleates, laurates, malates, fumarates, succinates, oxalates, tartarates, stearates, tolu-enesulfonates, methanesulfonates, 3-hydroxy-2-naphthoat.es and trifluoroacetates. Examples of salts with bases include, but are not limited to, lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, ammonium, meglumine and guanidinium salts.<br>
It is understood that the PDE4 inhibitors, the HMG-CoA reductase inhibitors as well as their pharma-ceutically acceptable salts can also be present in the form of their pharmaceutically acceptable sol¬vates and in particular in the form of their pharmaceutically acceptable hydrates.<br>
The combinations according to the invention may be administered by any suitable route, for example, by the oral, sublingual, buccal, intravenous, intraarterial, intramuscular, subcutaneous, intracutaneous, topical, transdermal, intranasal, intraperitoneal, rectal or vaginal route, by inhalation or by insufflation.<br>
Tablets, coated tablets (dragees), pills, cachets, capsules (caplets), granules, solutions, emulsions and suspensions are e.g. suitable for oral administration. In particular, said formulations can be adapted so as to represent, for example, an enteric form, an immediate release form, a delayed release form, a repeated dose release form, a prolonged release form or a sustained release form. Said forms can be obtained, for example, by coating tablets, by dividing tablets into several com¬partments separated by layers disintegrating under different conditions (e.g. pH conditions) or by coupling the active compound to a biodegradable polymer.<br>
Administration by inhalation is preferably made by using an aerosol. The aerosol is a liquid-gaseous dispersion, a solid-gaseous dispersion or a mixed liquid/solid-gaseous dispersion.<br>
The aerosol may be generated by means of aerosol-producing devices such as dry powder inhalers (DPIs), pressurized metered dose inhalers (PMDIs) and nebulizers. Depending on the kind of the active compound to be administered, the aerosol-producing device can contain the active compound in form of a powder, a solution or a dispersion. The powder may contain, for example, one or more of<br><br>
the following auxiliaries: carriers, stabilizers and fillers. The solution may contain in addition to the solvent, for example, one or more of the following auxiliaries: propellants, solubilizers (co-solvents), surfactants, stabilizers, buffers, tonicity adjusting agents, preservatives and flavorings. The dispersion may contain in addition to the dispersant, for example, one or more of the following auxiliaries: pro¬pellants, surfactants, stabilizers, buffers, preservatives and flavorings. Examples of carriers include, but are not limited to, saccharides, e.g. lactose and glucose. Examples of propellants include, but are not limited to, fluorohydrocarbons, e.g. 1,1,1,2-tetrafIuoroethane and 1,1,1,2,3,3,3-heptafluoropropane.<br>
The particle size of the aerosol particles (solid, liquid or solid/liquid particles) is preferably less than 100 urn, more preferably it is in the range of from 0.5 to 10 urn, in particular in the range of from 2 to 6 um (D50 value, measured by laser diffraction).<br>
For parenteral modes of administration such as, for example, intravenous, intraarterial, intramuscular, subcutaneous, intracutaneous and intraperitoneal administration, preferably solutions (e.g. sterile solutions, isotonic solutions) are used. They are preferably administered by injection or infusion techniques.<br>
The pharmaceutical compositions (formulations) comprising the PDE4 inhibitor or a pharmaceutically acceptable salt thereof and/or the HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable auxiliary can be manufactured in a manner known to a person skilled in the art, e.g. by dissolving, mixing, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. As pharmaceutically acceptable auxiliaries, any auxiliaries known to be suitable for preparing pharmaceutical compositions (formu¬lations) can be used. Examples thereof include, but are not limited to, solvents, excipients, disper-sants, emulsifiers, solubilizers, gel formers, ointment bases, antioxidants, preservatives, stabilizers, carriers, fillers, binders, thickeners, compiexing agents, disintegrating agents, buffers, permeation promoters, polymers, lubricants, coating agents, propellants, tonicity adjusting agents, surfactants, colorants, flavorings, sweeteners and dyes. In particular, auxiliaries of a type appropriate to the desired formulation and the desired mode of administration are used.<br>
The most preferred mode of administration of Roflumilast, Roflumilast-N-oxide or a pharmaceutically acceptable salt of either is oral. In another preferred embodiment Roflumilast, Roflumilast-N-oxide or a pharmaceutically acceptable salt of either is administered by intravenous infusion or injection. In a further embodiment Roflumilast, Roflumilast-N-oxide or a pharmaceutically acceptable salt of either is administered by intramuscular or subcutaneous injection. Other routes of administration are also con¬templated, including for example intranasal and transdermal routes, and by inhalation.<br><br>
The preferred mode of administration of the PDE4 inhibitors CILOMILAST, TETOMILAST, LIRIMI-LAST, L-869298, OGLEMILAST and COMPOUND A is oral, while the preferred mode of administra¬tion of the PDE4 inhibitors AWD-12-281 and TOFIMILAST is administration by inhalation.<br>
The preferred mode of administration of the HMG CoA reductase inhibitors LOVASTATIN, PRAVAS¬TATIN; SIMVASTATIN; ATORVASTATIN, FLUVASTATIN, ROSUVASTATIN, PRAVASTATIN, BER-VASTATIN, DALVASTATIN and GLENVASTATIN is oral.<br>
The exact dosage and regimen for administering a PDE4 inhibitor or a pharmaceutically acceptable salt thereof in combination with a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof will necessarily depend on the potency and duration of action of the active compounds used, the nature and severity of the inflammatory pulmonary disease to be treated, as well as the sex, age, weight, general health and individual responsiveness of the patient to be treated, and other relevant circumstances.<br>
As part of the combination therapy according to the invention the PDE4 inhibitor or a pharmaceutically acceptable salt thereof and the HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof are dosed in an order of magnitude customary for the mono-therapy, it more likely being pos¬sible, on account of the individual actions, which are mutually positively influencing and reinforcing, to reduce the respective doses on the combined administration of the PDE4 inhibitor or a pharmaceuti¬cally acceptable salt thereof and the HMG-CoA reductase inhibitor or a pharmaceutically acceptable saK thereof with the norm.<br>
Without intended to be limiting, the orally administered daily dosage (for an adult patient) of the PDE4 inhibitors or the pharmaceutically acceptable salts thereof will generally range from about 0.05 mg to about 200 mg; without intended to be limiting, the daily dosage (for an adult patient) of a PDE4 inhibi¬tor or a pharmaceutically acceptable salt thereof for administration by inhalation will generally range from 0.05 mg to about 100 mg.<br>
In the case of oral administration of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST) the daily dose (for an adult patient) for the mono-therapy is in the range from 50 to 1000 ug per day, preferably in the range of 50 to 500 ug per day, preferably by once daily administration. In the case of intravenous administration of 3-cyclopropylmethoxy-4-difluoro-methoxy-N-(3,5-dichloropyrid-4-yl)benzamide (ROFLUMILAST) the daily dose (for an adult patient) for the mono-therapy is in the range from 50 to 500 ug per day, preferably 150 to 300 ug per day.<br>
In the case of oral administration of CILOMILAST the daily dose (for an adult patient) for the mono¬therapy is likely to be in the range from 10 to 40 mg per day, preferably from 20 to 30 mg per day, preferably by twice daily administration.<br><br>
In the case of administration by inhalation of AWD-12-281 the daily dosage (for an adult patient) for the mono-therapy is likely to be in the range of 500 to 2000 pg per day.<br>
In the case of oral administration of LIRIMILAST the daily dosage (for an adult patient) for the mono¬therapy is likely to be in a range of 1 to 10 mg per day.<br>
In the case of oral administration of OGLEMfLAST the daily dosage (for an adult patient) for the mono¬therapy is likely to be in the range of 1 to 10 mg per day.<br>
In the case of oral administration of COMPOUND A the daily dosage (for an adult patient) for the mo¬notherapy is likely to be in a range of 0.1 to 10 mg once daily, preferably 0.1 to 2 mg once daily.<br>
The orally administered daily dosage (for an adult patient) of the HMG-CoA reductase inhibitors or the pharmaceutically acceptable salts thereof will generally range from about 0.01 mg to about 200 mg, preferably from 10 to 80 mg, more preferably from 5 to 40 mg; for administration by inhalation a dos¬age range of 0.001 mg to about 25 mg is preferred, even more preferable is a dosage from 0.1 to 25 mg.<br>
Table 3: Preferred Combinations<br><br>
Example Number	Combination<br>
1	ROFLUMILAST	LOVASTATIN<br>
2	ROFUJMILAST-N-Oxide	LOVASTATIN<br>
3	ROFLUMILAST	PRAVASTATIN<br>
4	ROFLUMILAST-N-Oxide	PRAVASTATIN<br>
5	ROFLUMILAST	PRAVASTATIN sodium<br>
6	ROFLUMILAST-N-Oxide	PRAVASTATIN sodium<br>
7	ROFLUMILAST	SIMVASTATIN<br>
8	ROFLUMILAST-N-Oxide	SIMVASTATIN<br>
9	ROFLUMILAST	ATORVASTATIN<br>
10	ROFLUMILAST-N-Oxide	ATORVASTATIN<br>
11	ROFLUMILAST	ATORVASTATIN hemi-calcium sesqui-hydrate<br><br>
Example Number	Combination<br>
12	ROFLUMILAST-N-Oxide	ATORVASTATIN hemi-calcium sesqui-hydrate<br>
13	ROFLUMILAST	FLUVASTATIN<br>
14	ROFLUMILAST-N-Oxide	FLUVASTATIN<br>
15	ROFLUMILAST	FLUVASTATIN sodium<br>
16	ROFLUMILAST-N-Oxide	FLUVASTATIN sodium<br>
17	ROFLUMILAST	ROSUVASTATIN<br>
18	ROFLUMILAST-N-Oxide	ROSUVASTATIN<br>
19	ROFLUMILAST	ROSUVASTATIN hemi-calcium<br>
20	ROFLUMILAST-N-Oxide	ROSUVASTATIN hemi-calcium<br>
21	ROFLUMILAST	ROSUVASTATIN sodium<br>
22	ROFLUMILAST-N-Oxide	ROSUVASTATIN sodium<br>
23	ROFLUMILAST	PRAVASTATIN<br>
24	ROFLUMILAST-N-Oxide	PRAVASTATIN<br>
25	ROFLUMILAST	PRAVASTATIN hemi-calcium<br>
26	ROFLUMILAST-N-Oxide	PRAVASTATIN hemi-calcium<br>
27	ROFLUMILAST	BERVASTATIN<br>
28	ROFLUMILAST-N-Oxide	BERVASTATIN<br>
29	ROFLUMILAST	DALVASTATIN<br>
30	ROFLUMILAST-N-Oxide	DALVASTATIN<br>
31	ROFLUMILAST	GLENVASTATIN<br>
32	ROFLUMILAST-N-Oxide	GLENVASTATIN<br>
33	CILOMILAST	LOVASTATIN<br>
34	CILOMILAST	PRAVASTATIN<br>
35	CILOMILAST	PRAVASTATIN sodium<br>
36	CILOMILAST	SIMVASTATIN<br>
37	CILOMILAST	ATORVASTATIN<br><br>
Example Number	Combination<br>
38	CI LOW I LAST	ATORVASTATIN hemi-calcium sesqui-hydrate<br>
39	CILOMILAST	FLUVASTATIN<br>
40	CILOMILAST	FLUVASTATIN sodium<br>
41	CILOMILAST	ROSUVASTATIN<br>
42	CILOMILAST	ROSUVASTATIN hemi-calcium<br>
43	CILOMILAST	ROSUVASTATIN sodium<br>
44	CILOMILAST	PRAVASTATIN<br>
45	CILOMILAST	PRAVASTATIN hemi-calcium<br>
46	CILOMILAST	BERVASTATIN<br>
47	CILOMILAST	DALVASTATIN<br>
48	CILOMILAST	GLENVASTATIN<br>
49	AWD-12-281	LOVASTATIN<br>
50	AWD-12-281	PRAVASTATIN<br>
51	AWD-12-281	PRAVASTATIN sodium<br>
52	AWD-12-281	SIMVASTATIN<br>
53	AWD-12-281	ATORVASTATIN<br>
54	AWD-12-281	ATORVASTATIN hemi-calcium sesqui-hydrate<br>
55	AWD-12-281	FLUVASTATIN<br>
56	AWD-12-281	FLUVASTATIN sodium<br>
57	AWD-12-281	ROSUVASTATIN<br>
58	AWD-12-281	ROSUVASTATIN hemi-calcium<br>
59	AWD-12-281	ROSUVASTATIN sodium<br>
60	AWD-12-281	PRAVASTATIN<br>
61	AWD-12-281	PRAVASTATIN hemi-calcium<br>
62	AWD-12-281	BERVASTATIN<br>
63	AWD-12-281	DALVASTATIN<br><br>
ExaTipie Number	Combination<br>
64	AWD-12-281	GLENVASTATIN<br>
65	TOFIMILAST	LOVASTATIN<br>
66	TOFIMILAST	PRAVASTATIN<br>
67	TOFIMILAST	PRAVASTATIN sodium<br>
68	TOFIMILAST	SIMVASTATIN<br>
69	TOFIMILAST	ATORVASTATIN<br>
70	TOFIMILAST	ATORVASTATIN hemi-calcium sesqui-hydrate<br>
71	TOFIMILAST	FLUVASTATIN<br>
72	TOFIMILAST	FLUVASTATIN sodium<br>
74	TOFIMILAST	ROSUVASTATIN<br>
75	TOFIMILAST	ROSUVASTATIN hemi-calcium<br>
76	TOFIMILAST	ROSUVASTATIN sodium<br>
77	TOFIMILAST	PRAVASTATIN<br>
78	TOFIMILAST	PRAVASTATIN hemi-calcium<br>
79	TOFIMILAST	BERVASTATIN<br>
80	TOFIMILAST	DALVASTATIN<br>
81	TOFIMILAST	GLENVASTATIN<br>
82	TETOMILAST	LOVASTATIN<br>
83	TETOMILAST	PRAVASTATIN<br>
84	TETOMILAST	PRAVASTATIN sodium<br>
85	TETOMILAST	SIMVASTATIN<br>
86	TETOMILAST	ATORVASTATIN<br>
87	TETOMILAST	ATORVASTATIN hemi-calcium sesqui-hydrate<br>
88	TETOMILAST	FLUVASTATIN<br><br>
Example Number	Combination<br>
89	TETOMILAST	FLUVASTATIN sodium<br>
90	TETOMILAST	ROSUVASTATIN<br>
91	TETOMILAST	ROSUVASTATIN hemi-calcium<br>
92	TETOMILAST	ROSUVASTATIN sodium<br>
93	TETOMILAST	PRAVASTATIN<br>
94	TETOMILAST	PRAVASTATIN hemi-calcium<br>
95	TETOMILAST	BERVASTATIN<br>
96	TETOMILAST	DALVASTATIN<br>
97	TETOMILAST	GLENVASTATIN<br>
98	OGLEMILAST	LOVASTATIN<br>
99	OGLEMILAST	PRAVASTATIN<br>
100	OGLEMILAST	PRAVASTATIN sodium<br>
101	OGLEMILAST	SIMVASTATIN<br>
102	OGLEMILAST	ATORVASTATIN<br>
103	OGLEMILAST	ATORVASTATIN hemi-calcium sesqui-hydate<br>
104	OGLEMILAST	FLUVASTATIN<br>
105	OGLEMILAST	FLUVASTATIN sodium<br>
106	OGLEMILAST	ROSUVASTATIN<br>
107	OGLEMILAST	ROSUVASTATIN hemi-calcium<br>
108	OGLEMILAST	ROSUVASTATIN sodium<br>
109	OGLEMILAST	PRAVASTATIN<br>
110	OGLEMILAST	PRAVASTATIN hemi-calcium<br>
111	OGLEMILAST	BERVASTATIN<br>
112	OGLEMILAST	DALVASTATIN<br>
113	OGLEMILAST	GLENVASTATIN<br>
114	COMPOUND A	LOVASTATIN<br><br>
Example Number	Combination<br>
115	COMPOUNDA	PRAVASTATIN<br>
116	COMPOUNDA	PRAVASTATIN sodium<br>
117	COMPOUND A	SIMVASTATIN<br>
118	COMPOUND A	ATORVASTATIN<br>
119	COMPOUNDA	ATORVASTATIN hemi-calcium sesqui-hydate<br>
120	COMPOUND A	FLUVASTATIN<br>
121	COMPOUND A	FLUVASTATIN sodium<br>
122	COMPOUND A	ROSUVASTATIN<br>
123	COMPOUND A	ROSUVASTATIN hemi-calcium<br>
124	COMPOUND A	ROSUVASTATIN sodium<br>
125	COMPOUND A	PITAVASTATIN<br>
126	COMPOUND A	PITAVASTATIN hemi-calcium<br>
127	COMPOUND A	BERVASTATIN<br>
128	COMPOUND A	DALVASTATIN<br>
129	COMPOUND A	GLENVASTATIN<br><br>
Pharmacology:<br>
Synergistic inhibitor1 °f LPS-induced systemic TNFa release in rats by a combination of ATORVASTATIN herr1'-03'0'11"1 sesqui-hydrate and 2-{4-[(4aS,8aR)-4-(3l4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahy ord-1H-phthalazin-2-y)-pipendin 1-Y)-acetamide \ COMPDUND A)<br>
Animals: male SpraqLJe Dawley rats 200-280 g<br>
Drugs: ATORVASTA'f'N hemi-calcium sesqui-hydrate (Alexis Pharmaceuticals, San Diego, CA, USA) and COMPOUND A (ALTANA Pharma, Konstanz, Germany).<br>
Methods: Drugs were administered by gavage as a methocel / polyethylenglycol 400 suspension 1 h before intravenous adfninistration of LPS (°-1 mg/kg)- Euthanasia was induced 90 minutes later by injecting pentobarbital (48 m9^9) ar,d heparin (1,000 U/kg). Heparinized blood was obtained by heart puncture. Blood was cfintrifuged (21,000 x g, 4°C, 15 min), and plasma samples were kept frozen at -80°C until determination of TNFa levels by a commercially available ELISA kit (Quantakine®M, Rat TNFa immunoassay, F*&amp;D, MN, USA).<br>
Statistics: All data an? 9'ven as mean ± SEM. Significances were calculated on the primary TNFa concentrations in comparison witn tn© LPS-challenged control group using ANOVA with subsequent Dunnett's Test provide0" ty GraphPadPrism software package. Differences with p 
Results: LPS-induced systemic TNFa release was dose dependently inhibited by COMPOUND A and MQRVfrSTMkU oafcoM^ E-QvaUies. at Q .14. Kqf\f% (f la,. \\aad 23. cao/kq, (fCo,. 2\,ce&amp;oac&amp;veA{. COMPOUND A at a d^se of 0.013 mg/kg (1% increase versus placebo) as well as ATORVASTATIN hemi-calcium sesqui-hydrate ala dose of 0.5 mg/kg (11% decrease versus placebo) showed no sig¬nificant effects. However combination of COMPOUND A (0.13 mg/kg) with ATORVASTATIN hemi-calcium sesqui-hydrate (0.5 mg/kg) unexpectedly led to a significant inhibition of &gt; 50% (P 
Conclusion: The com&amp;'nat'on of sub-effective doses of the PDE4 inhibitor COMPOUND A and the HMG-CoA reductase inhibitor ATORVASTATIN hemi-calcium sesqui-hydrate unexpectedly showed a potent (synergistic) and effective inhibition of inflammatory processes.<br><br>
Description of the figures:<br>
In the figures ATORVASTATIN hemi-calcium sesqui-hydrate is indicated simply as "ATORVASTATIN Ca"<br>
Figure 1: Inhibition of LPS-induced (systemic) TNFa release in rats by COMPOUND A<br>
Figure 2: Inhibition of LPS-induced (systemic) TNFa release in rats by ATORVASTATIN hemi-calcium sesqui-hydrate<br>
Figure 3: Inhibition of LPS-induced (systemic) TNFa release in rats by a combination of COM¬POUND A and ATORVASTATIN hemi-calcium sesqui-hydrate<br><br>
WE CLAIM :<br>
1.	Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor or a pharmaceutical^ acceptable salt thereof, an amount of a HMG-CoA reduc¬tase inhibitor or a pharmaceutical^ acceptable salt thereof, wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease, and at least one pharmaceutical^ acceptable auxiliary.<br>
2.	A combination product comprising the components: (A) an amount of a PDE4 inhibitor or a pharmaceutical^ acceptable salt thereof; (B) an amount of a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof; wherein the first and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pul¬monary disease and wherein each of the components (A) and (B) is formulated in admixture with at least one pharmaceutically acceptable auxiliary.<br>
3.	A kit comprising the components: (A) a pharmaceutical formulation including an amount of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof, in admixture with at least one pharmaceutically acceptable auxiliary; (B) a pharmaceutical formulation including an amount of a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, in admixture with at least one pharmaceutically acceptable auxiliary; wherein the first and the second amount to¬gether comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease.<br>
4.	Pharmaceutical composition, combination product or kit according to any one of claims 1, 2 or 3, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, ROF-LUMILAST N-Oxide, CILOMILAST, AWD-12-281, TOFIMILAST, TETOMILAST, URIMILAST, L-869298, OGLEMILAST, 2-{4-{{4aS, 8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a.5,8.8a-tetra-hydro-1H-phthalazin-2-yl]-piperidin-1-yl}-acetamide and a pharmaceutically acceptable salt of these compounds.<br>
5.	Pharmaceutical composition, combination product or kit according to any one of claims 1, 2 or 3, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a phar¬maceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceuti¬cally acceptable salt of ROFLUMILAST-N-oxide.<br>
6.	Pharmaceutical composition, combination product or kit according to any one of claims 1, 2, 3 or 5, wherein the PDE4 inhibitor is ROFLUMILAST.<br><br>
7.	Pharmaceutical composition, combination product or kit according to any one of claims 1, 2, 3 or 5, wherein the PDE4 inhibitor is ROFLUMILAST-N-oxide.<br>
8.	Pharmaceutical composition, combination product or kit according to any one of claims 1, 2 or 3, wherein the PDE4 inhibitor is CILOMILAST or a pharmaceutical^ acceptable salt thereof.<br>
9.	Pharmaceutical composition, combination product or kit according to any one of claims 1,2 or 3, wherein the PDE4 inhibitor is AWD-12-281 or a pharmaceutically acceptable salt thereof.<br>
10.	Pharmaceutical composition, combination product or kit according to any one of claims 1, 2 or 3, wherein the PDE4 inhibitor is TOFIMILAST or a pharmaceutical^ acceptable salt thereof.<br>
11.	Pharmaceutical composition, combination product or kit according to any one of claims 1, 2 or 3, wherein the PDE4 inhibitor is TETOMILAST or a pharmaceutical^ acceptable salt thereof.<br>
12.	Pharmaceutical composition, combination product or kit according to any one of claims 1, 2 or 3, wherein the PDE4 inhibitor is OGLEMILAST or a pharmaceutical^ acceptable salt thereof.<br>
13.	Pharmaceutical composition, combination product or kit according to any one of claims 1 to 12, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of LOVASTA-TIN, PRAVASTATIN, SIMVASTATIN, ATORVASTATIN, FLUVASTATIN, ROSUVASTATIN, Pl-TAVASTATIN, BERVASTATIN, DALVASTATIN, GLENVASTATIN and the pharmaceutically ac¬ceptable salts of these compounds.<br>
14.	Pharmaceutical composition, combination product or kit according to any one of claims 1 to 12, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of ATORVAS¬TATIN, SIMVASTATIN, PRAVASTATIN, ROSUVASTATIN and the pharmaceutically acceptable salts of these compounds.<br>
15.	Pharmaceutical composition, combination product or kit according to any one of claims 1 to 14, wherein the inflammatory pulmonary disease is selected from the group consisting of asthma, COPD, sclerosis, alveolitis, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hyperten¬sion.<br><br>
16.   Process for the preparation of a pharmaceutical composition as defined in any one of claims 1 and 4 to 15 which comprises mixing the PDE4 inhibitor or a pharmaceutically acceptable salt thereof with the HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof.<br><br>
Dated this 29th day of January, 2009<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktYWJzdHJhY3QuZG9j" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-abstract.doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ0xBSU1TKEFNRU5ERUQpLSgyMC05LTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CLAIMS(AMENDED)-(20-9-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ0xBSU1TKEFNRU5ERUQpLSgyMi0yLTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CLAIMS(AMENDED)-(22-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ0xBSU1TKEFNRU5ERUQpLSgyMy0xMC0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CLAIMS(AMENDED)-(23-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ0xBSU1TKE1BUktFRCBDT1BZKS0oMjAtOS0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CLAIMS(MARKED COPY)-(20-9-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ0xBSU1TKE1BUktFRCBDT1BZKS0oMjItMi0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CLAIMS(MARKED COPY)-(22-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktY2xhaW1zLmRvYw==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-claims.doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktY2xhaW1zLnBkZg==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoMTYtNi0yMDExKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(16-6-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoMTktMTItMjAxMSkucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(19-12-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoMi0xMi0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(2-12-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoMi02LTIwMTApLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(2-6-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoMjQtNS0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(24-5-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoMjYtNC0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(26-4-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoMjgtMTAtMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(28-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoMjgtNS0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(28-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoNC0xMi0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(4-12-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktQ09SUkVTUE9OREVOQ0UoOS03LTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-CORRESPONDENCE(9-7-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktY29ycmVzcG9uZGVuY2UucGRm" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZGVzY3JpcHRpb24oY29tcGxldGUpLmRvYw==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-description(complete).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZGVzY3JpcHRpb24oY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZHJhd2luZy5wZGY=" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-drawing.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRU5HTElTSCBUUkFOU0xBVElPTigyNi00LTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-ENGLISH TRANSLATION(26-4-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRVAgRE9DVU1FTlQoMTItMTEtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-EP DOCUMENT(12-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAxKDIzLTEwLTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 1(23-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAxKDI5LTEtMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 1(29-1-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAxMygyNi00LTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 13(26-4-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAxMygyOS0xLTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 13(29-1-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZm9ybSAxMy5wZGY=" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAxOCgyLTYtMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 18(2-6-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAyKFRJVExFIFBBR0UpLSgyMy0xMC0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 2(TITLE PAGE)-(23-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZm9ybSAyKHRpdGxlIHBhZ2UpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-form 2(title page).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZm9ybSAyLmRvYw==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-form 2.doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZm9ybSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDEyLTExLTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(12-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDE2LTYtMjAxMSkucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(16-6-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDE5LTEyLTIwMTEpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(19-12-2011).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDItMTItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(2-12-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDI0LTUtMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(24-5-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDI4LTEwLTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(28-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDI4LTUtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(28-5-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDQtMTItMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(4-12-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktRk9STSAzKDktNy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-FORM 3(9-7-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktR0VORVJBTCBQT1dFUiBPRiBBVFRPUk5FWSgyNi00LTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-GENERAL POWER OF ATTORNEY(26-4-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktZ2VuZXJhbCBwb3dlciBvZiBhdHRvcm5leS5wZGY=" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-general power of attorney.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktSkFQQU5FU0UgRE9DVU1FTlQoMTItMTEtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-JAPANESE DOCUMENT(12-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktT1RIRVIgRE9DVU1FTlQoMjAtOS0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-OTHER DOCUMENT(20-9-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktT1RIRVIgRE9DVU1FTlQoMjYtNC0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-OTHER DOCUMENT(26-4-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktcGN0IHJlcXVlc3QucGRm" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-pct request.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktcGN0LWliLTMwNC5wZGY=" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-pct-ib-304.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktcGN0LWliLTMwNi5wZGY=" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-pct-ib-306.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktcGN0LWliLTM3My5wZGY=" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-pct-ib-373.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktcGN0LWlzYS0yMTAucGRm" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-pct-isa-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktcGN0LWlzYS0yMzcucGRm" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-pct-isa-237.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktUEVUSVRJT04gVU5ERVIgUlVMRS0xMzcoMjMtMTAtMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-PETITION UNDER RULE-137(23-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktUkVQTFkgVE8gRVhBTUlOQVRJT04gUkVQT1JUKDEyLTExLTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-REPLY TO EXAMINATION REPORT(12-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktUkVQTFkgVE8gRVhBTUlOQVRJT04gUkVQT1JUKDIyLTItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-REPLY TO EXAMINATION REPORT(22-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktUkVQTFkgVE8gSEVBUklORygyMC05LTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-REPLY TO HEARING(20-9-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktUkVQTFkgVE8gSEVBUklORygyMy0xMC0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-REPLY TO HEARING(23-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LU1VTU5QLTIwMDktVVMgRE9DVU1FTlQoMTItMTEtMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">214-MUMNP-2009-US DOCUMENT(12-11-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktd28gaW50ZXJuYXRpb25hbCBwdWJsaWNhdGlvbiByZXBvcnQgYTIucGRm" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-wo international publication report a2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjE0LW11bW5wLTIwMDktd28gaW50ZXJuYXRpb25hbCBwdWJsaWNhdGlvbiByZXBvcnQgYTMucGRm" target="_blank" style="word-wrap:break-word;">214-mumnp-2009-wo international publication report a3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QxLmpwZw==" target="_blank" style="word-wrap:break-word;">abstract1.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="258348-method-and-system-for-chemical-and-physical-characterization-of-complex-samples.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="258350-hydroentangled-product-comprising-cellulose-fibers.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>258349</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>214/MUMNP/2009</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>01/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>03-Jan-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>01-Jan-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>29-Jan-2009</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>TAKEDA GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>BYK-GULDEN-STR. 2, 78467 KONSTANZ, GERMANY</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ANDREA WOHLSEN</td>
											<td>RUE DE LA COTE 22, 2000 NEUCHATEL,</td>
										</tr>
										<tr>
											<td>2</td>
											<td>STEFAN-LUTZ WOLLIN</td>
											<td>MALZERGASSE 3, 88339 BAD WALDSEE,</td>
										</tr>
										<tr>
											<td>3</td>
											<td>CLEMENS BRAUN</td>
											<td>SEPP-BIEHLER STR. 3, 78464 KONSTANZ,</td>
										</tr>
										<tr>
											<td>4</td>
											<td>DEGENHARD MARX</td>
											<td>OBERE REUTE 15, 78345 MOOS,</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K31/44</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2007/056683</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2007-07-03</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>06116625.2</td>
									<td>2006-07-05</td>
								    <td>EPO</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/258349-combination-of-hmg-coa-reductase-inhibitor-with-phosphodiesterase-4-inhibitors-for-the-treatmentof-inflammatory-pulmonary-diseases by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 05:52:56 GMT -->
</html>
